To search for anti-cancer agents, a screening system for Ras signal inhibitors was developed using a NIH3T3 cell line with an introduced reporter gene which is controlled by the Ras-responsive element (RRE). With this screening system, malolactomycin D was identi®ed as a selective inhibitor of transcription from the RRE. This compound was found to preferentially inhibit the anchorageindependent growth rather than the anchorage-dependent growth of Ras-transformed NIH3T3 cells. The expression of matrix metalloproteinases MMP-1 and MMP-9, which have RRE in their promoters, were reduced by treatment with malolactomycin D at the translational and transcriptional levels. Analysis of the activity of mitogenactivated protein (MAP) kinases, which play important roles in transduction of the Ras signal, showed that malolactomycin D inhibits the activation of p38 MAP kinase and Jun N-terminal-kinase (JNK) but not extracellular signal-regulated kinase 1 or 2 (ERK1 or 2). These ®ndings suggest that by inhibiting the pathway that leads to the activation of p38 MAP kinase and JNK, malolactomycin D suppresses the expression of MMPs. Since MMPs play important roles in metastasis and maintenance of the microenvironment of tumor cells, both of which facilitate tumor growth, the inhibition of MMPs by malolactomycin D is believed to contribute to its ability to inhibit Ras-mediated tumorigenesis. Oncogene (2001) 20, 6724 ± 6730.
Introduction
Point mutational activation of ras oncogenes and/or their gene ampli®cation occur in many types of human cancers (reviewed by Bos, 1989; Corominas et al., 1991; Nishimura and Sekiya, 1987) . Therefore, inhibition of Ras-mediated signal transduction should be eective for development of novel anti-cancer agents which are more eective and less toxic. In fact, there are now many studies on the development of farnesyltransferase inhibitors which block farnesylation of Ras (Rowinsky et al., 1999) . Additional sites downstream of Ras should be targeted to inhibit Ras-mediated signal transduction. We previously discovered trichostatin A as an inhibitor of Ras-mediated signal transduction, by assay of the reversion activity of the ras-transformed phenotype of NIH3T3 cells to normal. (Futamura et al., 1995) . Since trichostatin A is an inhibitor of histone deacetylase involved in regulation of the expression of numerous genes, it may also aect growth of normal cells as well as tumor cells. (Burke and Baniahmad, 2000; Kuo and Allis, 1998) . Therefore, more speci®c inhibitors of the Ras signal would be preferable to minimize general cytotoxicity. There are reports that in Ras signal transduction, activated Ras stimulates transcription from the Rasresponsive element (RRE) or RRE-like enhancer elements upstream of genes such as c-fos, MMP-1, MMP-3 and MMP-9, which are considered to take part in tumorigenicity (Bortner et al., 1993; Gum et al., 1996; Imler et al., 1988; Watabe et al., 1998; White et al., 1997) . Therefore, compounds capable of inhibiting transcription from the RRE would be useful as anti-cancer agents.
To screen inhibitors of transcription from the RRE, we established a cell line from NIH3T3 cells by introduction of both a luciferase reporter gene under the transcriptional control of the RRE and a gene expression vector containing the oncogenic ras gene. As a control, we also introduced a Renilla luciferase vector without RRE, pRL0-luc, which has been shown not to respond to oncogenic Ras (Behre et al., 1999) . On screening using this cell line, malolactomycin D was identi®ed as a selective inhibitor of Ras-responsive transcription. Malolactomycin D was originally reported to have anti-fungal activity (Tanaka et al., 1997) . However, the anti-tumor activity of this compound has not yet been investigated. Here we demonstrate that malolactomycin D inhibits Ras signaling pathways and Ras-mediated transformation.
responsive element (RRE). To evaluate the inhibitory eect of test compounds on transcription from the RRE in cells, we used a reporter plasmid, pRRE-luc expressing the ®re¯y luciferase gene under the transcriptional control of the RRE. As a control, a promoterless Renilla luciferase vector, pRL0-luc, was employed to exclude nonspeci®c inhibitors such as general cytotoxic agents.
Before setting up the screening system using a stable transformed cell line, the transcriptional response of these reporter genes to Ras signal was examined. The pRRE-luc plasmid was transiently transfected into NIH3T3 cells with either an expression vector containing the c-H-ras val12 gene or an empty expression vector. The pRL0-luc plasmid was also transfected into NIH3T3 cells with either the ras-expression vector or the empty expression vector. Then, the luciferase activity of each plasmid was measured (Figure 1 ). In pRRE-luc, the luciferase activity was increased approximately ®vefold by oncogenic c-H-Ras val12 , while the pRL0-luc did not respond to the Ras signal. These results con®rmed that oncogenic c-H-Ras val12 speci®cally activates transcription from the RRE in this system.
Identification of inhibitors of RRE-dependent transcription
To set up the screening system for RRE transcription inhibitors, we established a stable cell line designated as RRE/RL0/ras from NIH3T3 cells by co-transfection of the luciferase reporter plasmids, pRRE-luc, pRL0-luc and the gene expression vector containing oncogenic c-H-ras val12 . Using this cell line, the ability of test compounds to inhibit the transcription mediated by the RRE were evaluated in comparison with their inhibitory eect on the transcription driven by the RL0 control element.
On screening of more than 15 000 samples of culture broth extract of microorganism, such as fungus and actinomycetes, etc., we isolated two active ingredients that selectively inhibited the RRE transcription. These ingredients were identi®ed as radicicol (Soga et al., 1998) and malolactomycin D. In addition, we identi®ed another active chemical compound, L-783,277 (Zhao et al., 1999) from a chemical compound library, which consists of 10 000 synthetic compounds with various structures. Among these hit compounds, radicicol and L-783,277 are already known to aect the Ras signaling pathway. Radicicol was previously reported to inhibit Raf-1 activity and thereby disrupt the Ras and Raf dependent signal pathway (Soga et al., 1998) . This compound suppressed the transcription of the pRRE-luc and the promoterless pRL0-luc with an IC 50 value of 0.4 mg/ml and 2.7 mg/ml, respectively. L-783,277 was previously identi®ed as an inhibitor of MAP kinase kinase 1 (MEK1) (Zhao et al., 1999) . MEK1 is known to be located downstream of the Ras signaling pathway Van Aelst et al., 1993; Winitz et al., 1993) . This compound suppressed 50% of the transcription of the pRRE-luc and the pRL0-luc at 0.1 and 0.8 mg/ml, respectively. Therefore, it is conceivable that these compounds could suppress RRE transcription by inhibiting the Raf or Ras signaling pathway. On the other hand, malolactomycin D was previously reported as an anti-fungal agent (Tanaka et al., 1997) . However, its eect on the Ras signaling pathways are unknown. In this screening, malolactomycin D was the most selective inhibitor of transcription from the RRE among the active compounds thus far obtained. This compound suppressed the transcription of the pRRE-luc with an IC 50 value of 0.9 mg/ml, whereas it suppressed the transcription of the promoterless pRL0-luc with an IC 50 value of 11.9 mg/ml (Figure 2 ).
Inhibition of anchorage-independent cell growth by RRE transcription inhibitors
To investigate whether these active compounds obtained in the screening can suppress transformation activity in Ras-transformed cells, we evaluated their inhibitory eect on the cell growth under both anchorage-independent and anchorage-dependent conditions. Malolactomycin D inhibited the anchorageindependent cell growth in soft agar with an IC 50 value of 1.2 mg/ml (Figure 3 ). In contrast, it did not inhibit anchorage-dependent cell growth under the same conditions. A much higher concentration of malolactomycin D (8.3 mg/ml) was required to inhibit anchoragedependent cell growth. These results indicated that On the contrary, the radicicol and`MEK1 inhibitor', L-783,277, inhibited anchorage-independent and anchorage-dependent cell growth equally (data not shown). Therefore, we decided to perform a more detailed study on malolactomycin D.
Northern blot analysis of Ras-inducible genes in the presence of malolactomycin D
Since malolactomycin D inhibited RRE-dependent transcription, this compound might suppress the transcription of Ras-inducible genes containing RRE in the cells. The transcription of several important genes associated with tumorigenesis, metastasis and the mitogenic response are known to be transcribed from RRE or RRE-like elements by the Ras signal. Accordingly, we investigated the eect of malolactomycin D on the expression of the Ras-inducible genes MMP-1, MMP-9 and c-fos.
Oncogenic Ras-transformed NIH3T3 cells were treated with various concentrations of malolactomycin D (0.5 ± 15.0 mg/ml). Then the expression of mRNA of MMP-1, MMP-9 and c-fos genes were analysed by Northern blotting (Figure 4) . When the cells were treated with 1.5 mg/ml of malolactomycin D, the levels of mRNA of MMP-1 and MMP-9 were clearly suppressed by 75 and 68%, respectively. To con®rm whether malolactomycin D selectively suppresses the transcription of MMPs that contain RRE-like elements, we examined the eect of this compound on the expression of MMP-2, which lacks the RRE-like element (Corcoran et al., 1996; Qin et al., 1999) . In contrast to MMP-1 and MMP-9, the level of mRNA of MMP-2 was little aected by the addition of 1.5 mg/ml of malolactomycin D. The expression of MMP-2 mRNA was only reduced by 42% even in the presence of 15.0 mg/ml of malolactomycin D. These observations suggested that malolactomycin D does not suppress the transcription of genes that do not have the RRE-like element.
It is notable that the expression of mRNA of c-fos was not in¯uenced by treatment with malolactomycin D, although c-fos has the RRE. From these results, we concluded that the expression of some Ras-inducible genes containing RRE were inhibited by malolactomycin D while others were not. Therefore, we tried to ®nd out what caused this dierence.
Detection of MMP-production by zymography
We next examined whether the production of MMP-1, MMP-9 and MMP-2 proteins were reduced by treatment with malolactomycin D by zymography. Zymography is a sensitive method for determination of secreted MMPs proteins in cell culture supernatant (Heussen and Dowdle, 1980) . Ras-transformed NIH3T3 cells were treated with 0.5 ± 15.0 mg/ml of malolactomycin D and then the activities of MMP-1, MMP-9 and MMP-2 proteins in the supernatant were measured ( Figure 5 ). The amounts of 57 KD/MMP-1 and 105 KD/MMP-9 proteins were reduced by malolactomycin D treatment in a dose-dependent manner and the concentration of 1.5 mg/ml of malolactomycin D was sucient to reduce most of the production of MMP-1 and MMP-9 proteins. In contrast, the production of 72 KD/MMP-2 was not reduced with 1.5 mg/ml of malolactomycin D. The production of MMP-2 protein remained at half the control level even with 15.0 mg/ml of malolactomycin D ( Figure 5 ). These results showed that malolactomycin D can reduce the expression of MMP-1 and MMP-9 at the protein level as well as at the transcriptional level.
Inhibition of MAP kinase activity by malolactomycin D
The dierence in the inhibitory eect of malolactomycin D on the expression of mRNA of MMP-1/ 9 and cfos led us to examine the eect of this compound on molecules in the signaling pathways that are thought to be involved in the regulation of the transcription of these genes. Several experiments have provided evidence that the upregulation in expression of several Ras-inducible genes with RRE sequences are relayed through dierent MAP kinase pathways. The expression of MMP-1 and MMP-9 were shown to be regulated by the RRE-binding transcription factors Ets-1 and AP1, which seem to be primarily activated via p38 MAP kinase and JNK-dependent pathway in various transformed cells (Brauchle et al., 2000; Buttice et al., 1996; Himelstein et al., 1998; Johansson et al., 2000; Newberry et al., 1997; Simon et al., 1998) . On the other hand, the transcriptional activation of the c-fos gene by proliferational signals seems to be largely dependent on the ERK1, 2 cascades which activate the binding of the Elk-1 transcription factor to the RRE (Hodge et al., 1998; Price et al., 1996) . Accordingly, we investigated the eect of malolactomycin D on the growth factor-dependent activation of the MAP kinases p38 MAP kinase, JNK and ERK1, 2. Among various growth factors, bFGF has been shown to be one of those which are capable of upregulating the expression of the MMP-1, MMP-9 and c-Fos in NIH3T3 cells (Aho et al., 1997; Spencer et al., 1999) . In preliminary experiment, we con®rmed that malolactomycin D inhibits the bFGF-stimulated expression of MMP-1 and MMP-9 mRNA in NIH3T3 cells (data not shown).
When bFGF was added to NIH3T3 cells in the absence of malolactomycin D, activation of p38 MAP kinase, JNK and ERK1, 2 were observed ( Figure 6 ). In the presence of 5.0 mg/ml of malolactomycin D, the activation of p38 MAP kinase by bFGF was disrupted almost completely. In addition, the activation of JNK by bFGF was in part (68%) impaired by treatment with 5.0 mg/ml of malolactomycin D. In contrast, the activation of ERK1, 2 was not clearly aected by malolactomycin D treatment. These results indicated that abrogation of the pathways of p38 MAP kinase and JNK but not ERK1, 2 by malolactomycin D results in inhibition of the transcription of MMPs but not c-fos.
Discussion
Activation of the Ras signaling pathway is a major molecular event in the development of human cancers (reviewed by Bos, 1989; Corominas et al., 1991; Nishimura and Sekiya, 1987) . Thus the Ras signaling pathway should be a promising target for development of new anti-cancer agents. To ®nd inhibitors of the Ras signaling pathway, we developed a screening system to monitor the inhibition of Ras-responsive transcription, using a reporter-gene assay. On screening of a large number of natural compounds, we identi®ed malolactomycin D as a selective inhibitor of RRE transcription and found that this compound preferentially inhibits the anchorage-independent growth of Ras-transformed cells. The results suggested that the growth-inhibitory eect of malolactomycin D was not due to general cytotoxicity but to speci®c blockage of the transforming signal derived from Ras. Therefore, we speculated that malolactomycin D could inhibit transformation activity of tumor cells without aecting normal cell growth. On investigation of the expression level of Rasinducible genes which have RRE or RRE-like elements in their promoter regions (Bortner et al., 1993; Gum et al., 1996; Imler et al., 1988; Watabe et al., 1998; White et al., 1997) , we found that malolactomycin D eciently reduced the expression of MMP-1 and MMP-9. In contrast, it did not inhibit the expression of MMP-2, which lacks a RRE-like element (Corcoran et al., 1996; Qin et al., 1999) . MMP-1 and MMP-9 have been shown to play important roles in tumor invasion and metastasis by facilitating extracellular matrix degradation and by maintaining the tumor microenvironment to enhance tumor growth (reviewed by Curran and Murray, 1999; Kleiner and Stetler-Stevenson, 1999; Westermarck and Kahari, 1999) . Therefore, malolactomycin D may suppress the transformation activity of Ras-transformed cells by inhibiting the expression of Ras-inducible genes such as MMP-1 and MMP-9.
On the other hand, malolactomycin D did not inhibit expression of the c-fos gene, which has been shown to contain a RRE. The expression of c-fos is upregulated by various proliferational signal pathways, including the Ras signaling pathway, and is involved in normal cell growth as well as tumor cell growth (Goustin et al., 1986) . This may explain why malolactomycin D had little eect on the anchoragedependent growth which is considered a characteristic of normal cells, while it suppressed anchorageindependent growth which is considered a characteristic of malignant cells. In the present study, we also obtained other Ras-responsive transcription inhibitors, radicicol (Soga et al., 1998) and L-783,277 (Zhao et al., 1999) . However, these compounds inhibited both anchorage-independent and anchorage-dependent growth of the cells. Both radicicol and L-783,277 are thought to suppress the proliferation by inhibiting the Ras-Raf-MEK-ERK signal pathway which is linked to expression of the c-fos gene. Therefore, these compounds aect anchorage-dependent cell growth.
On analysis of the eect of malolactomycin D on MAPK activity, we found that malolactomycin D strongly inhibited phosphorylation of p38 MAP kinase by bFGF stimulation and partially decreased phosphorylation of JNK but had little eect on the phosphorylation of ERK1, 2. It has been reported that p38 MAP kinase and JNK but not ERK1, 2 are involved in the transcriptional activation of MMP-1 by FGF in MC3T3-E1 cells (Newberry et al., 1997) . In another report, the activity of p38 MAP kinase was shown to be involved in MMP-1 and MMP-9 expression by TNF-a and TGF-b in HaCaT cells and UT-SCC-7 cells (Johansson et al., 2000) . In addition, inhibition of p38 MAP kinase by its speci®c inhibitor, SB203580, was shown to block PMA-induced MMP-9 secretion and in vitro invasion in the human squamous cell carcinoma cell line (UM-SCC-1) (Simon et al., 1998) . From these ®ndings, it can be concluded that inhibition of p38 MAP kinase-and JNK-mediated pathways by malolactomycin D would contribute to inhibition of the expression of MMP-1 and MMP-9. This possibility was supported by our preliminary observation that inhibition of p38 MAP kinase activity by SB203580 resulted in reduction of MMP-1 and MMP-9 in Ras-transformed NIH3T3 cells (data not shown). On the other hand, ERK1, 2 are reported to activate c-fos gene transcription (Hodge et al., 1998; Price et al., 1996) . Therefore, it is likely that malolactomycin D had little eect on the expression of c-fos because it did not inhibit the activity of ERK1, 2.
The present data showed that malolactomycin D inhibited the expression of the Ras-inducible genes MMP-1 and MMP-9, and thereby suppressed the Rasinduced transformed phenotype. This suggests that MMPs are important for conferring the ability of anchorage-independent growth to cells, as well as facilitating invasion and metastasis. Therefore, speci®c reduction of expression of MMPs may be eective means to inhibit tumor development by suppressing cell growth, invasion and metastasis. We also empha- Figure 6 Eect of malolactomycin D on MAP kinases. Serum starved Ras-transformed NIH3T3 cells were incubated with bFGF alone or in combination with various concentrations of malolactomycin D for 10 min. The levels of activated p38 MAP kinase, JNK (46 kDa) and ERK1, 2 were determined by Western blot analysis using phosphospeci®c antibodies. The levels of total p38 MAP kinase, JNK and ERK1, 2 in the same samples were also determined using anti-p38 MAP kinase, anti-JNK and anti-ERK1, 2 antibodies, respectively size that our screening system for inhibitors of transcription through the RRE is useful in search for other inhibitors of Ras-dependent malignancy.
We are now examining the eect of malolactomycin D on tumor growth in animals.
Materials and methods

Construction of luciferase reporter gene vectors
Synthetic oligonucleotides derived from the RRE sequence (Reddy et al., 1992) were linked to an enhancerless thymidine kinase promoter, and were placed upstream of a luciferase reporter gene in a pGL2 basic vector (Promega). This construction was designated as pRRE-luc reporter plasmid. As a control, a pRL0-luc vector (Promega) for Renilla luciferase that lacks the eukaryotic promoter and enhancer elements was used.
Cells
NIH3T3 cells were purchased from Dainippon Pharmaceutical Co., Ltd.. A stable cell line designated as RRE/RL0/ras was established by the transfection of NIH3T3 cells with the reporter plasmids, pRRE-luc, pRL0-luc and a gene expression vector containing activated c-H-ras val12 (Newbold and Overell, 1983) . All cell lines were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 5% calf serum under humidi®ed air with 5% CO 2 at 378C.
Luciferase assay
For a transient transfection assay, 2610 5 cells were plated in 60 mm tissue culture plates. After 18 h incubation, the cells were transfected by the LIPOFECTAMINE method (Life Technologies, Grand Island, NY, USA) with either the reporter plasmids and a gene expression vector containing activated c-H-ras val12 or the reporter plasmids and an empty vector. Fire¯y and Renilla luciferase activities were measured after further incubation for 24 h by using a Dual-luciferase TM Reporter Assay System (Promega).
For screening for RRE-transcription inhibitors, 1610 4 cells/well were seeded into 96 well plates. After 1 day of culture, test compounds were added, and the plates were incubated further for 8 h. Luciferase activity was measured using the Dual-luciferase kit from Promega.
Soft agar assay
Soft agar assays were carried out in 24-well plates previously lined with 0.6% agar in DMEM (5% calf serum) containing various concentrations (0.2 ± 16.7 mg/ml) of malolactomycin D. Ras-transformed NIH3T3 cells were seeded at a density of 2610 3 cells/well in DMEM (5% calf serum) containing 0.3% agar. Prior to addition of the cell suspension, 0.1 ml of serial dilution of malolactomycin D or medium alone as a negative control were added. After incubation for 10 days at 378C in the presence of 5% CO 2 , colonies in each well were stained with piodotetrazolium violet (0.5 mg/ml), and the numbers of colonies were counted using a colony counter (PCA-11, Systemscience, Co., Ltd.)
Northern blot hybridization
Total cellular RNA was isolated from Ras-transformed NIH3T3 cells by the single-step method of Chomczynski and Sacchi (1987) . Aliquots of total RNA (16 ± 20 mg) were fractionated in 0.8% agarose gel containing 2.2 M formaldehyde and transferred to nitrocellulose membranes. The transferred RNAs on the membranes were hybridized with cDNA probes labeled with a-32 P-dCTP by random priming extension (Stratagene, La Jolla, CA, USA). For the hybridization, speci®c probes (0.5 ± 0.6 kb fragments) of MMPs were synthesized by PCR ampli®cation from NIH3T3 cell cDNA. A probe for c-fos was purchased from Takara Co.. The hybridized RNAs with the probes were quanti®ed by autoradiography. Glyceraldehyde-3-phosphate dehydrogenase mRNA was used as a control to determine the integrity of RNA and equality of the loading.
Zymography
Enzymatic activity of MMP proteins was determined by zymography as reported previously (Heussen and Dowdle, 1980) . Brie¯y, after 24 h incubation of Ras-transformed NIH3T3 cells with various concentrations of malolactomycin D, aliquots of the conditioned media containing 50 mg of protein were mixed with loading buer and proteins were separated under nonreduction conditions in 11% polyacrylamide gels containing with 1 mg/ml gelatin (Sigma). Then, the gels were washed with 2.5% Triton X-100 and incubated at 378C for 24 h in 50 mM Tris-HCl (pH 7.5) buer containing 0.15 M NaCl, 5 mM CaCl 2 , 1 mM ZnSO 4 and 40 mmol/l NaN 3 . After staining with Coomassie brilliant blue, MMP activity was evident as clear bands against a blue background.
Western blot analysis of MAP kinases
The activation of p38 MAP Kinase, JNK, and ERK1, 2 were determined by Western blotting using speci®c antibodies for phosphorylated forms of the corresponding MAP kinases (New England Biolabs, Beverly, MA, USA). NIH3T3 cells were seeded in DMEM containing 0.5% calf serum and incubated for 24 h. Basic ®broblast growth factor (bFGF) was added with or without various concentrations of malolactomycin D. After 10 min incubation, the cells were lysed in 62.5 mM Tris-HCl (pH 7.5) buer containing 2% SDS, 50 mM DTT and 10% glycerol. Equal amounts of the protein extracts were separated in 10% SDS ± PAGE and transferred to Hybond ECL membranes (Amersham Pharmacia Biotech). Western blotting was performed using phosphospeci®c antibodies for p38 MAP kinase, JNK and ERK1, 2, at 1 : 1000 dilution. Each protein was also probed with anti-p38 MAP kinase, anti-JNK and anti-ERK1, 2 antibodies (New England Biolabs, Beverly, MA, USA) to indicate equivalent amounts of protein in all lanes. Speci®c bindings of the antibodies were detected with peroxidase-conjugated secondary antibodies and developed with an enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech).
